Sonic Healthcare Reports Strong FY2025 Financial Performance

Sonic Healthcare Limited ( (SKHHY) ) has released its Q4 earnings. Here is a breakdown of the information Sonic Healthcare Limited presented to its investors.

Sonic Healthcare Limited is a leading global healthcare provider specializing in laboratory and radiology services, with operations spanning across Australia, New Zealand, Europe, and the USA. The company is recognized for its comprehensive diagnostic services and strategic acquisitions that enhance its market presence.

Sonic Healthcare Limited reported a robust financial performance for the fiscal year ending June 30, 2025, with revenue reaching AUD 9.65 billion, marking a 7.6% increase from the previous year. The company’s profit after tax attributable to members was AUD 513.6 million, reflecting a slight increase of 0.5% year-over-year. The company maintained a progressive dividend policy, with a final dividend of 63 cents per share, consistent with the previous year.

Key financial highlights include an 8% growth in EBITDA to AUD 1.725 billion, driven by organic revenue growth and cost efficiency programs. The company also completed the acquisition of LADR Laboratory Group in Germany, which is expected to contribute to future earnings growth. Sonic’s laboratory segment in Europe showed significant growth, while the radiology segment in Australia experienced strong organic revenue growth of 10%. The company’s strategic initiatives and acquisitions are anticipated to yield substantial synergies in the coming years.

Looking ahead, Sonic Healthcare is optimistic about its growth prospects, projecting strong earnings growth for FY2026, supported by organic growth, synergies from recent acquisitions, and strategic initiatives in the US market. The company expects EBITDA growth of up to 13% on a constant currency basis, with EPS growth potentially reaching 19% at current exchange rates.